![Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three‐factor model | Request PDF Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three‐factor model | Request PDF](https://www.researchgate.net/publication/358653567/figure/fig1/AS:1141764689788930@1649229323618/PFS-and-OS-of-338-CLL-patients-receiving-an-ibrutinib-based-therapy-OS-analysis-of_Q320.jpg)
Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three‐factor model | Request PDF
![Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia | Nature Communications Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-023-37648-w/MediaObjects/41467_2023_37648_Fig1_HTML.png)
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia | Nature Communications
![Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2152265019303982-fx2.jpg)
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
![Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | Annals of Hematology Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | Annals of Hematology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00277-021-04536-6/MediaObjects/277_2021_4536_Fig1_HTML.png)
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | Annals of Hematology
![Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2152265019303982-fx1.jpg)
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
![PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib](https://www.researchgate.net/publication/363193523/figure/fig4/AS:11431281082636186@1662086926633/Overall-survival-and-treatment-free-survival-among-patients-with-CLL-disease-progression_Q320.jpg)
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
![PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib](https://www.researchgate.net/publication/363193523/figure/fig2/AS:11431281082626222@1662086926570/Overall-survival-from-time-of-CLL-progression-on-ibrutinib-by-line-of-therapy-A-It_Q320.jpg)
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
![PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib](https://www.researchgate.net/publication/363193523/figure/fig5/AS:11431281082606564@1662086926671/Survival-outcomes-following-CLL-progression-on-ibrutinib-by-subsequent-line-of-therapy-A_Q320.jpg)
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
![Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/093b1ff9-754b-4f26-b2f9-af10e91b6372/gr4_lrg.jpg)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
![Full article: Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 Full article: Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3](https://www.tandfonline.com/cms/asset/dcce04c1-a450-4686-bc64-acb666725598/ilal_a_2020779_f0003_c.jpg)
Full article: Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3
![Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/0ad37857-ee38-42b3-8a93-8161f0727504/gr2.jpg)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
![Percentages of undetectable MRD (uMRD) in peripheral blood (PB) and... | Download Scientific Diagram Percentages of undetectable MRD (uMRD) in peripheral blood (PB) and... | Download Scientific Diagram](https://www.researchgate.net/publication/335480184/figure/fig2/AS:11431281154003464@1682616147256/Percentages-of-undetectable-MRD-uMRD-in-peripheral-blood-PB-and-bone-marrow-BM_Q320.jpg)
Percentages of undetectable MRD (uMRD) in peripheral blood (PB) and... | Download Scientific Diagram
![Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | Annals of Hematology Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | Annals of Hematology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00277-021-04536-6/MediaObjects/277_2021_4536_Fig4_HTML.png)